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impact on how patients feel or function, which summarizes health-related quality 
of life (HRQoL). Contemporary mCRPC therapies have shown survival improvements 
and varying HRQoL impacts. In order to understand the true burden of illness (BOI) 
in these patients and how it is impacted by treatment, it is critical to understand 
how patient-centered outcomes are measured and interpreted. METHODS: This lit-
erature review identified MEDLINE publications reporting on HRQoL (including pain) 
in ≥ 50 mCRPC patients using predefined search terms: prostate, prostate cancer, 
castrate- or hormone-resistant, hormone refractory, androgen-independent, andro-
gen independence and quality of life, HRQoL, pain, bone or cancer-related pain, 
fatigue, and weight loss. RESULTS: Forty-four mCRPC studies were identified that 
met prespecified criteria and included 14 unique HRQoL instruments. Important 
HRQoL issues for mCRPC patients included pain, nausea/vomiting, and insomnia. 
The most commonly used measures were EORTC QLQ-C30, FACT-P, and the BPI/
McGill pain questionnaires. Most of these instruments were not specifically devel-
oped for mCRPC patients and may not comprehensively capture symptoms impor-
tant to this population. Further, identified studies did not use consistent definitions 
of clinically meaningful differences. Since 2010, using a variety of instruments in 
pivotal studies, 3 treatments (mitoxantrone, estramustine phosphate and doc-
etaxel, and cabazitaxel) had no statistically significant impacts on HRQoL or pain, 
whereas 4 other treatments (abiraterone, enzalutamide, radium-223, and sipuleu-
cel-T) reported statistically significant benefits for HRQoL or pain. CONCLUSIONS: 
HRQoL is an important complement to survival and other clinical endpoints to best 
understand treatment benefit in mCRPC. To give context to the relative impact of 
treatments on HRQoL, it is critical to understand the underlying BOI in this patient 
population and to standardize methods for measuring and quantifying the assess-
ment of HRQoL in mCRPC.
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OBJECTIVES: There is no evidence about the appropriateness of the EQ-5D (a 
generic preference-based measure of health) in Myelofibrosis (MF), a rare but seri-
ous bone-marrow cancer. This study aimed to provide psychometric evidence of its 
appropriateness. METHODS: Convergent validity and responsiveness of the EQ-5D 
was assessed by comparing it to a condition-specific measure, the MF Symptom 
Assessment Form (MFSAF) in 48 patients with MF with repeated measurement over 
48 weeks using data from the ROBUST study. Convergent validity was based on 
correlation analysis between EQ-5D utility scores and dimensions (mobility, usual 
activities, self-care, pain/discomfort and anxiety/depression) and MFSAF total score 
and symptoms (pain, early satiety, night sweats, itching and bone or muscle pain). 
Responsiveness was based on change in EQ-5D compared to change in MFSAF using 
standardized response mean (SRM) and Cohen’s effect size (ES). Moderate to strong 
correlations (rho> |0.3|) and comparable SRM and ES would indicate that EQ-5D 
was appropriate. RESULTS: EQ-5D had poor associations with key symptoms in MF 
(rho< |0.3|), except for the ‘pain/discomfort’ and ‘anxiety/depression’ health dimen-
sions (rho> |0.4|). SRM and ES at week 4 for EQ-5D was 0.270 and 0.343 compared to 
SRM and ES of 0.911 and 0.826 for the MF-SAF. A large proportion (15.56%) reported 
no problems in EQ-5D dimensions at baseline. The MFSAF total score did not show 
comparable ceiling effect (4.76%). There was however some indication of ceiling 
effect for some of the individual dimension of the MFSAF indicating that patients 
in this sample did not all have the common MF symptom. CONCLUSIONS: This 
exploratory analysis suggests that the EQ-5D’s ability to capture the effect of key 
symptoms in MF is limited to pain rather than the specific MF symptoms such as 
night sweats and itchiness. However, results of this analysis need to be interpreted 
with caution due to the small number of patients.
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OBJECTIVES: The aim of this study was to evaluate the associations between quality 
of life (QoL) domains and frequency of readmission to hospitals for different cancer 
patients. A secondary aim was to observe if the increased number of outpatient 
clinic admissions resulted an increased number of hospitalizations. METHODS: 
We evaluated QoL (EORTC QoL Questionnaire-C30) and hospital admissions in 
350 patients with lung, breast, hematological, head and neck, colorectal, gastric, 
gynecological, and prostate cancers. The outpatient clinic admission and hospi-
talization data for each patient within 1-year of QoL assessment was obtained 
from the hospital finance database. Statistical analyses used nonparametric correla-
tion coefficients to flag associations (r> 0.3 and p< 0.05) between overall, functional 
or symptom scales and number of hospitalizations or outpatient clinic admis-
sions. RESULTS: QoL domains associated with readmissions within 3 months were, 
emotional functioning (r= 0.42, p= 0.003) and global health status (r= 0.51, p< 0.001) for 
gastric cancers. For readmissions within 1 year they were nausea/vomiting symp-
tom scales (r= 0.44, p= 0.002) for colorectal cancer and global health status (r= 0.46, 
p= 0.001) for gastric cancers. Constipation (r= 0.32, p= 0.025) and nausea/vomiting 
scales (r= 0.32, p= 0.024) for breast cancers were associated with hospitalizations 
within 3 months. Diarrhea symptom scale (r= 0.35, p= 0.013) for colorectal cancers 
and appetite loss scale (r= 0.55, p= 0.016) for prostate cancers were associated with 
hospitalizations within 1 year. In general, number of hospitalizations and admis-
sions were not significantly correlated except for the head and neck cancers (r= 0.32, 
p= 0.022, within 1 year). CONCLUSIONS: Several quality of life domains might be 
associated with hospital admissions and hospitalizations. Although they may not 
always reflect causal relations, these QoL evaluations may be used to flag possible 
increases in contact with health care system and to timely notify the patient or their 
relatives of this possibility. Increased number of clinic visits does not necessarily 
result in increased hospitalizations for most cancer types.
FACT Lym MF symptoms. A large proportion (n> 50%) reported no problems (ceiling 
effects) in QLQ-C30 dimensions (nausea/vomiting, constipation/diarrhoea). There 
was some evidence of ceiling effects in MF symptoms in COMFORT II due to miss-
ing data which affects the analysis. CONCLUSIONS: QLQ-C30 reflected functional 
and fatigue effects of MF but was less associated with MF specific symptoms such 
as itching and night sweats which are important MF symptoms. The QLQ-C30 pain 
dimension showed less responsiveness than the MF specific pain dimensions. 
QLQ-C30 dimensions related to constipation and diarrhoea were less relevant in 
this population than has been found in other cancer populations.
PCN124
dErivatioN of a PrEfErENCE-basEd mEasurE for mEtastatiC brEast 
CaNCEr usiNg thE EortC qlq-30 aNd qlq-br 23
Hudgens S1, Lloyd A2, Campbell P1, Harrington A1, Forsythe A3
1Clinical Outcomes Solutions, Tucson, AZ, USA, 2Bladon Associates Ltd, Oxford, UK, 3Eisai, 
Woodcliff Lake, NJ, USA
OBJECTIVES: Psychometric analyses to derive a health state classification system 
in multiple myeloma using the European Organization for Research and Treatment 
of Cancer Core Quality of Life Questionnaire (EORTC QLQ-30) were used to esti-
mate a preference-based measure for health state utility derivation (Rowen et al. 
2011). This study sought to apply a modified Rowen framework to identify EORTC 
QLQ-30 and the breast module (QLQ-BR23) items amenable to valuation to esti-
mate a preference-based measure in metastatic breast cancer (MBC). METHODS: 
Exploratory factor analysis, Rasch analysis and other psychometric analyses 
were undertaken on the 53 item EORTC tools using baseline Phase 3 clinical trial 
data on 1063 patients with MBC to identify items amenable to valuation. Criteria 
for item identification were: factor loading > 0.4; < 50% of respondents at ceil-
ing/floor; mean square fit statistics between 0.5 and 1.5; and ordered category 
response. RESULTS: Nine dimensions were identified on the EORTC dataset via 
exploratory factor analysis. Potential items, stratified by dimension, deemed useful 
for valuation include: physical (QLQ-30 items 1, 2, 6, 7, 27 and QLQ-BR23 item 6), 
cognitive/emotional (QLQ-30 items 21, 22, 23 and 24), self-image (QLQ-BR23 items 
9, 10, 11 and 12), breast symptoms (QLQ-BR23 item 20), fatigue/sleep disturbance 
(QLQ-30 items 10, 12 and 18), arm pain (QLQ-BR23 item 17), and general pain 
(QLQ-30 item 9). Items related to gastrointestinal and sexual symptoms were not 
considered due to the measurement criteria. CONCLUSIONS: Twenty of 53 items 
suitable for valuation were identified over seven dimensions of the EORTC QLQ-
30 and QLQ-BR 23. Items that did not meet the specified criteria for inclusion 
may be utilized for health state derivation if they represent clinically significant 
components of MBC. Results of the created health state classification system for 
valuation and derivation of a preference-based measure for metastatic breast 
cancer will be presented.
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OBJECTIVES: Two effective therapies, enzalutamide and AbP, emerged simulta-
neously for treating patients with mCRPC that has progressed on or after doc-
etaxel (post-chemotherapy setting) and yet are not compared head-to-head. 
This study aims to assess the comparative effectiveness of these treatments on 
QoL. METHODS: A systematic literature review of MEDLINE, Embase, Cochrane, 
and controlled trials registries was conducted to identify all evidence on the treat-
ment effect of enzalutamide and AbP on patients’ QoL in the post-chemotherapy 
setting. Since there are no trials directly comparing these treatments, an adjusted 
indirect comparison (Bucher et al. 1997) was performed on improvement and time 
to deterioration in FACT-P total score and subdomains. Results are expressed as odds 
ratio or hazard ratio with corresponding 95% confidence intervals (CIs). RESULTS: 
Two randomized, placebo-controlled, Phase III studies (AFFIRM and COU-AA-301) 
were identified and included in the analysis. The studies had similar study popula-
tions and designs but used different comparators (placebo in AFFIRM; prednisone in 
COU-AA-301) which were assumed to be similar. The same pre-specified criteria for 
clinically meaningful improvement and deterioration in FACT-P outcomes were used 
in both studies (Cella et al. VIH2009). Compared with AbP, enzalutamide significantly 
increased the likelihood of QoL improvement on the FACT-P total score (odds ratio 
[95% CI]: 1.94 [1.15; 3.27]), functional wellbeing (1.85 [1.09; 3.14]), and prostate cancer 
subscales (PCS) (1.79 [1.10; 2.90]). Enzalutamide significantly decreased the risk of 
QoL deterioration in FACT-P total score (hazard ratio [95% CI]: 0.72 [0.54; 0.95]) and 
PCS (0.75 [0.58; 0.98]) vs. AbP. CONCLUSIONS: The impact of enzalutamide on QoL 
in the post-chemotherapy setting compares favorably with AbP, with significantly 
higher odds of QoL improvement and significant delay in QoL deterioration, subject 
to study assumptions. The adjusted indirect comparison method can shed light 
on relative benefits of effective therapies that have not been formally compared.
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OBJECTIVES: Survival is the predominant measure of metastatic castration-resist-
ant prostate cancer (mCRPC) treatment benefit, but it does not account for the 
